Sacituzumab Govitecan Plus Pembrolizumab Shows Promise for Bladder Sparing in Muscle-Invasive Cancer
Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...
Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...
"The next decade will witness an unprecedented convergence of powerful therapeutics, precise biomarkers, and personalized strategies creating a watershed moment to redefine muscle-invasive bladder ...
Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk for ...
TAR-200 achieved an 82% tumor elimination rate in high-risk non-muscle-invasive bladder cancer patients resistant to previous treatments. The device releases gemcitabine into the bladder over three ...
After decades of limited options, a groundbreaking FDA-approved treatment is opening new doors for people with certain types of bladder cancer. Supported by Johnson & Johnson Bill is a real patient ...
The Root on MSN
Influencer Explains Why Her Bladder Collapsed At The Gym
After lifting too heavy at the gym, one TikToker is telling her viewers about experiencing a bladder prolapse.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results